Journal of the National Cancer Institute
-
J. Natl. Cancer Inst. · Nov 1997
Randomized Controlled Trial Clinical TrialTamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer. ⋯ Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.